Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**ACT-541468 + citalopram** is a combination of two pharmaceutical drugs: daridorexant (code name ACT-541468), a dual orexin receptor antagonist being developed for the treatment of insomnia, and citalopram, a selective serotonin reuptake inhibitor (SSRI) widely approved for the treatment of major depressive disorder and other psychiatric conditions. Daridorexant promotes sleep via antagonism of orexin receptors OX1R and OX2R, which regulate wakefulness, while citalopram increases serotonin activity in the CNS by inhibiting its reuptake, thereby exerting antidepressant and anxiolytic effects. Co-administration is under clinical evaluation for pharmacokinetic and pharmacodynamic safety and tolerability in healthy individuals, with minor interaction effects and safety confirmed for doses up to 50 mg daridorexant with citalopram[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ACT-541468 + citalopram.